

**Supplemental document S1.** Supplemental references for Table 2.

- I. Passoni, L., et al. *Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.* Cancer Res, 2009. **69**(18):p. 7338-7346.
- II. Shukla, N., et al. *Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.* Clin Cancer Res, 2012. **18**(3):p. 748-757.
- III. Corao, D., et al. *ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.* Pediatr Dev Pathol, 2009. **12**(4):p. 275-283.
- IV. Yoshida, A., et al. *Anaplastic lymphoma kinase status in rhabdomyosarcomas.* Mod Pathol, 2013. **26**(6):p. 772-781.
- V. Fleuren, E., et al. *Expression and clinical relevance of MET and ALK in Ewing sarcomas.* Int J Cancer, 2013. **133**(2):p. 427-436.
- VI. Dirks, W., et al. *Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines.* Int J Cancer, 2002. **100**(1):p. 49-56.
- VII. Zhang, J., et al. *Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.* Nat Genet, 2013. **45**(6):p. 602-612.
- VIII. Kong, D., et al. *Prognostic significance of c-Met expression in glioblastomas.* Cancer, 2009. **115**(1):p. 140-148.
- IX. Diomedi-Camassei, F., et al. (2008). *Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma.* Clin Cancer Res, 2008 **14**(13):p. 4119-4127.
- X. Thorarinsdottir, H., et al. *Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.* Clin Cancer Res, 2008. **14**(11):p. 3386-3394.
- XI. Bax, D., et al. *EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.* Clin Cancer Res, 2009. **15**(18):p. 5753-5761.
- XII. Izycka-Swieszewska, E., et al. *EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.* Folia Neuropathol, 2010. **48**(4):p. 238-245.
- XIII. Freeman, S., et al. *Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.* Cancer, 2008. **113**(6):p. 1453-1461.
- XIV. Vasei, M., et al. *Amplification and expression of EGFR and ERBB2 in Wilms tumor.* Cancer Genet Cytogenet, 2009. **194**(2):p. 88-95.
- XV. Ganti, R., et al. *Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.* Mod Pathol, 2006. **19**(9):p. 1213-1220.
- XVI. Dobashi, Y., al. *EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.* Mod Pathol, 2009. **22**(10):p. 1328-1340.
- XVII. Meurer, R., et al. *Immunohistochemical expression of markers Ki-67, neuron, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters.* Arq Neuropsiquiatr, 2008. **66**(2B):p. 385-390.
- XVIII. Ragab, S., et al. *HER2/neu expression: a predictor for differentiation and survival in children with Wilms tumor.* Pathol Oncol Res, 2010. **16**(1):p. 61-67.
- XIX. Shang, J., et al. *Integrated assessment of potential value of erbB-2 amplification or expression status as novel therapy target in Chinese children and adolescents with osteosarcoma.* Chin Med J (Engl), 2009. **122**(13):p. 1521-1524.

- XX. Pollack, I., et al. *O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort*. J Clin Oncol, 2006. **24**(21):p. 3431-3437.
- XXI. Zarghooni, M., et al. *Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets*. J Clin Oncol, 2010. **28**(8):p. 1337-1344.
- XXII. Paugh, B., et al. *Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas*. Cancer Res, 2013. **73**(20):p. 6219-6229.
- XXIII. Robinson, S., et al. *Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas*. Neurosurgery, 2001. **48**(4):p. 864-873; discussion 873-864.
- XXIV. Eggert, A., et al. *High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas*. Clin Cancer Res, 2000. **6**(5): 1900-1908.
- XXV. Moreno, L., et al. *Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma*. J Neurooncol, 2013. **111**(2):p. 169-176.
- XXVI. Armistead, P. M., et al. *Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients*. Cancer, 2007. **110**(10):p. 2293-2303.
- XXVII. Bozzi, F., E., et al. *Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors*. Cancer, 2007. **109**(8):p. 1638-1645.
- XXVIII. Do, I., et al. *Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas*. Pathol Res Pract, 2007. **203**(3):p. 127-134.
- XXIX. Liang, M., et al. *Tyrosine kinase expression in pediatric high grade astrocytoma*. J Neurooncol, 2008. **87**(3):p. 247-253.
- XXX. Shimada, A., et al. *Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma*. Pediatr Blood Cancer, 2008. **50**(2):p. 213-217.
- XXXI. Dalla-Torre, C. A., et al. *Effects of THBS3, SPARC and SPPI expression on biological behavior and survival in patients with osteosarcoma*. BMC Cancer, 2006. **6**: 237.
- XXXII. Leblebisatan, G., et al. *Vascular endothelial growth factor levels in childhood acute lymphoblastic and myeloblastic leukemia*. Indian J Hematol Blood Transfus, 2012. **28**(1):p. 24-28.